drugset

drugset / Trial / NCT01737944

Exposure Study Comparing 3 Routes of Methotrexate (MTX) Administration

NCT01737944 ↗

Phase 1/2 Completed 38 enrolled Antares Pharma Inc.

RandomizedCrossoverOpen-labelTreatment

Summary

Pharmacokinetics (PK) study

Timeline

Start: 2011-01
Primary completion: 2011-05
Completion: 2011-06

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Methotrexate	Small molecule	10 mg	Subcutaneous
Subject	Methotrexate	Small molecule	15 mg	Subcutaneous
Subject	Methotrexate	Small molecule	20 mg	Subcutaneous
Subject	Methotrexate	Small molecule	25 mg	Subcutaneous

Indications